The US Food and Drug Administration isn't expecting all Rx-to-OTC switch applications it receives will include an extra-label component to help guide consumers' self-selection, but it's ready to talk to potential switch sponsors about novel proposals.
Before focusing on developing novel switch proposals, though, firms should be certain the ingredients they're studying won't muster FDA approval...







